66491-03-0

Basic information

• Product Name: 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE
• Synonyms: 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE;7-aMino-3;1(2H)-Isoquinolinone, 7-aMino-3,4-dihydro-;7-Amino-3,4-dihydro-1(2H)-isoquinolinone
• CAS NO: 66491-03-0
• Molecular Formula: C₉H₁₀N₂O
• Molecular Weight: 162.19
• Mol File: 66491-03-0.mol
• Article Data: 17

Chemical Properties

• Melting Point: 123-125 °C
• Boiling Point: 495.9°C at 760 mmHg
• Flash Point: 253.7°C
• Appearance: /
• Density: 1.237g/cm³
• Vapor Pressure: 5.69E-10mmHg at 25°C
• Refractive Index: 1.621
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 14.96±0.20(Predicted)
• CAS DataBase Reference: 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(66491-03-0)
• EPA Substance Registry System: 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(66491-03-0)

Safety Data

• Hazardous Substances Data: 66491-03-0(Hazardous Substances Data)

Usage

Description

7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE is an organic compound with the molecular formula C9H10N2O. It is a derivative of isoquinoline, which is a heterocyclic compound with a fused benzene and pyridine ring. 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE is characterized by the presence of an amino group at the 7th position, and it plays a significant role in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE is used as a reactant in the preparation of dihydroisoquinolinones. These dihydroisoquinolinones are potent inhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme that plays a crucial role in DNA repair and regulation of cell death. By inhibiting PARP, these compounds can potentially enhance the effectiveness of certain cancer treatments, particularly in tumors with DNA repair deficiencies.
The application of 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE in the pharmaceutical industry is primarily focused on the development of novel therapeutic agents for cancer treatment. Its role in the synthesis of PARP inhibitors highlights its importance in the ongoing research and development of targeted cancer therapies.

InChI:InChI=1/C9H10N2O/c10-7-2-1-6-3-4-11-9(12)8(6)5-7/h1-2,5H,3-4,10H2,(H,11,12)

Upstream product

• 22245-96-1 7-nitro-3,4-dihydro-2H-isoquinolin-1-one 
• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 1196-38-9 3,4-dihydroisoquinolin-1(2H)-one 
• 6552-60-9 3,4-dihydro-2H-isoquinoline-1-thione 
• 2257-09-2 Phenethyl isothiocyanate 
• 86288-79-1 2,7-Dinitro-3,4-dihydroisocarbostyryl 
• 6970-83-8 ethyl-N-(2-phenethyl)carbamate 
• 64-04-0 phenethylamine 
• 83-33-0 inden-1-one 

Downstream Products

• 66491-04-1 7-iodo-3,4-dihydro-1(1H)-isoquinolinone 
• 1196-38-9 3,4-dihydroisoquinolin-1(2H)-one 
• 891782-60-8 7-bromo-3,4-dihydroisoquinolin-1(2 H)-one 
• 709040-12-0 1-(8-amino-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2,6-dichloro-phenyl)-thiourea 
• 1027936-01-1 [1-Oxo-7-(1-trityl-1H-imidazol-4-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid 
• 183622-32-4 ethyl 7-(1-trityl-4-imidazolyl)-3,4-dihydro-1(1H)-isoquinolinone-2-acetate 
• 1028295-53-5 4-{2-[((R)-1-Ethoxycarbonylmethyl-3-phenyl-propylcarbamoyl)-methyl]-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl}-piperazine-1-carboxylic acid tert-butyl ester 
• 1027838-11-4 (S)-3-{2-[1-Oxo-7-(1-trityl-1H-imidazol-4-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-acetylamino}-3-pyridin-3-yl-propionic acid ethyl ester 
• 1026704-88-0 4-{2-[((S)-2-Benzenesulfonylamino-2-ethoxycarbonyl-ethylcarbamoyl)-methyl]-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl}-piperazine-1-carboxylic acid tert-butyl ester 
• 182198-53-4 L-767,679 
• 22245-96-1 7-nitro-3,4-dihydro-2H-isoquinolin-1-one 
• 62541-63-3 5-Iodo-2-(2-pyrrol-1-ylethyl)benzoic acid 
• 62541-67-7 2-(2-Pyrrol-1-ylethyl)-5-nitro benzoic acid 
• 62541-66-6 2-(2-Aminoethyl)-5-nitrobenzoic acid 

Relevant articles and documents

1,2,4-Triazole-3-Thione Analogues with a 2-Ethylbenzoic Acid at Position 4 as VIM-type Metallo-β-Lactamase Inhibitors

Metallo-β-lactamases (MBLs) are increasingly involved as a major mechanism of resistance to carbapenems in relevant opportunistic Gram-negative pathogens. Unfortunately, clinically efficient MBL inhibitors still represent an unmet medical need. We previou

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.